Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/19/2003WO2003050254A2 Novel chimeric tnf ligands
06/19/2003WO2003050252A2 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use
06/19/2003WO2003050247A2 Antisense modulation of mhc class ii transactivator expression
06/19/2003WO2003050246A2 Antisense modulation of nod1 expression
06/19/2003WO2003050245A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
06/19/2003WO2003050244A2 Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
06/19/2003WO2003050241A2 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
06/19/2003WO2003050238A2 Receptor-targeted adenoviral vectors
06/19/2003WO2003050236A2 Human genes and gene expression products isolated from human prostate
06/19/2003WO2003050141A2 Calpain activators
06/19/2003WO2003050139A2 Prion inhibiting peptides and derivatives thereof
06/19/2003WO2003050136A2 Peptide t stimulates ctl responses
06/19/2003WO2003050133A1 Antisense modulation of estrogen receptor beta expression
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003049783A2 Device and methods for harvesting tissue samples of known geometry
06/19/2003WO2003049762A2 Immunisation against chlamydia trachomatis
06/19/2003WO2003049761A1 Use of insuline-like growth factor-i for promoting remyelination of axons
06/19/2003WO2003049760A1 Compositions and method for treating hepatitis virus infection
06/19/2003WO2003049759A1 Agonists and antagonists of oxifan for the treatment of metabolic disorders
06/19/2003WO2003049758A1 Emergen agonists and antagonists for use in the treatment of metabolic disorders
06/19/2003WO2003049757A1 Agonists and antagonists of glucomin for the treatment of metabolic disorders
06/19/2003WO2003049756A1 Glucomin agonists and antagonists for use in the treatment of metabolic disorders
06/19/2003WO2003049754A1 The use of osteogenic growth peptide in the enhancement of haemopoiesis
06/19/2003WO2003049743A1 Combination cancer therapy
06/19/2003WO2003049734A1 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
06/19/2003WO2003049725A2 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
06/19/2003WO2003049717A2 Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
06/19/2003WO2003049703A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
06/19/2003WO2003049700A2 Growth hormone releasing hormone suplementation for treating chronically ill subjects
06/19/2003WO2003049697A2 Treatment of glioblastoma with thymosin-alpha 1
06/19/2003WO2003049694A2 Methods of therapy for non-hodgkin's lymphoma
06/19/2003WO2003049693A2 Method and composition for inducing weight loss
06/19/2003WO2003049691A2 Antisense modulation of pctaire protein kinase 1 expression
06/19/2003WO2003049687A2 Medicinal compositions & therapeutic methods
06/19/2003WO2003049686A2 Stabilization of hypoxia inducible factor (hif) alpha
06/19/2003WO2003049684A2 Pseudo-antibody constructs
06/19/2003WO2003049682A2 Composition and method for treating chronic allograft rejection
06/19/2003WO2003049673A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003WO2003049669A2 Methods, devices, and preparations for intervertebral disc treatment
06/19/2003WO2003049626A1 Method and apparatus for production of a skin graft and the graft produced thereby
06/19/2003WO2003035002A3 Management of postoperative pain
06/19/2003WO2003028657A3 Compositions for oral gene therapy and methods of using same
06/19/2003WO2003028545A3 Method, instruments, and kit for autologous transplantation
06/19/2003WO2003020252A3 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
06/19/2003WO2003013438A3 Nutrient therapy for immuno-compromised patients
06/19/2003WO2003009777A3 Delivery of therapeutic capable agents
06/19/2003WO2003007882A3 Method of making bowman-birk inhibitor product
06/19/2003WO2002094864A3 Human cdnas and proteins and uses thereof
06/19/2003WO2002088172B1 Pentapeptide compounds and uses related thereto
06/19/2003WO2002083914A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
06/19/2003WO2002070755A3 Fen endonucleases
06/19/2003WO2002068584A3 Antisense modulation of cytohesin-1 expression
06/19/2003WO2002062847A3 Superficial zone protein and methods of making and using same
06/19/2003WO2002051429A3 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
06/19/2003WO2002048326A8 Human caplain proteins and polynucleotides coding therefor
06/19/2003WO2002048172A3 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
06/19/2003WO2002044342A9 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
06/19/2003WO2002042462A3 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
06/19/2003WO2002034899A3 Tec kinase assay
06/19/2003WO2002030979A3 Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same
06/19/2003WO2002029058A3 Human proteins, polynucleotides encoding them and methods of using the same
06/19/2003WO2002022153A3 Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
06/19/2003WO2002020801A3 26199, 33530, 33949, 47148, 50226, and 58764, human transferase family members and uses therefor
06/19/2003WO2002012343A3 Proteins and nucleic acids encoding g-protein coupled receptors
06/19/2003WO2002010205A3 Mutations of the mdr1 p-glycoprotein that improve its ability to confer resistance to chemotherapeutic drugs
06/19/2003WO2002008244A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus
06/19/2003WO2002004514A3 Compositions and methods for the therapy and diagnosis of lung cancer
06/19/2003WO2001015676A9 Compositions and methods for modulating hdl cholesterol and triglyceride levels
06/19/2003WO2001008635A3 Calcium channel transport polynucleotides, polypeptides, and antibodies
06/19/2003US20030115632 Diacylglycerol acyl transferase proteins
06/19/2003US20030115617 Transgenic animal; antidiabetic agents, anxiolytic agents, analgesics, antiepileptic agents
06/19/2003US20030114724 Polyubiquitin based hydrogel and uses thereof
06/19/2003US20030114678 Cardioprotective phosphonates and malonates
06/19/2003US20030114677 Cardioprotective phosphonates and malonates
06/19/2003US20030114659 Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
06/19/2003US20030114658 Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
06/19/2003US20030114657 Central nervous system disorders; brain disorders
06/19/2003US20030114652 Hybrid polypeptide; genetic engineering
06/19/2003US20030114650 Modulation gene expression
06/19/2003US20030114646 Human cystatin F
06/19/2003US20030114643 Regulation of human serotonin-like g protein-coupled receptor
06/19/2003US20030114529 HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation
06/19/2003US20030114514 Preventing collagen-based leukocyte adhesion and leukocyte adhesion
06/19/2003US20030114412 Antisense modulation of RECQL5 expression
06/19/2003US20030114410 Angiogenesis inhibition by administering into the tissue a molecule ,e.g., novel platelet factor 4 binding protein, to deactivate a lysyl oxidase; antimetastasis, -carcinogenic and -tumor agents; suppression of fibrosis
06/19/2003US20030114407 Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
06/19/2003US20030114406 Dihydrazide derivatized hyaluronic acid crosslinked to a nucleic acid to transfect a cell, e.g. heart cell, to encoding a protein, e.g., endotheilial growth factor, to increase angiogenesis; antiischemic agents
06/19/2003US20030114404 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
06/19/2003US20030114402 Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
06/19/2003US20030114400 Oligonucleotide hybridizes with nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha to inhibits gene expression; antiproliferative, -carcinogenic and -inflammatory agents
06/19/2003US20030114389 Combination of organic compounds
06/19/2003US20030114388 Auxiliary agents for ophthalmic operation
06/19/2003US20030114387 Gamma secretase inhibitors
06/19/2003US20030114386 Anticancer agents, angiogenesis inhibitors
06/19/2003US20030114384 Methods and compositions for treating lesions of the respiratory epithelium
06/19/2003US20030114383 Calcitonin-like sequence expressed by gonadotropes of the anterior pituitary
06/19/2003US20030114382 Angiogenesis inhibition
06/19/2003US20030114380 Amino acid sequence has 87-99 peptide residues
06/19/2003US20030114379 Encoded protein for treating leukemia, leukocytes, and bone marrow stem cell colony formation
06/19/2003US20030114378 Mouse pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
1 ... 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 ... 3163